论文部分内容阅读
唑来膦酸对早期RA的结构改变有益英国研究人员对随机接受唑来膦酸或安慰剂治疗的早期RA和有手/腕滑膜炎的39例患者的研究显示,唑来膦酸组26周时磁共振显像(MR)手和腕损害的平均数较安慰剂组下降61%。损伤的手和腕骨升高的平均数在唑来膦酸组为0．3士0．75,在安慰剂组为1．4±1．77。唑来膦酸组MR上显示有新的骨肿胀的患者比例数少于对照组。唑来膦酸组放射学损伤数目的平均改变为0．1,而安慰剂组为0．5。两组安全性相似。结果表明,初步证据显示唑来膦酸治疗对RA患者的结构改变有益(Arthritis Rheum,2006,54：1410～1414).
Zoledronic acid is beneficial for structural alterations in early RA British researchers studied 39 patients with early RA and hand / wrist synovitis randomized to zoledronic acid or placebo, which showed that the zoledronic acid group 26 The average number of magnetic resonance imaging (MR) hand and wrist injuries decreased by 61% compared with placebo during the week. The average number of lesions in the injured hand and carpal was 0.3 ± 0.75 in the zoledronic acid group and 1.4 ± 1.77 in the placebo group. The proportion of patients on the zoledronic acid group MR showing new bone swelling was less than that of the control group. The average change in the number of radiological lesions in the zoledronic acid group was 0.1 compared with 0.5 in the placebo group. The safety of the two groups is similar. The results show that preliminary evidence suggests that zoledronic acid therapy may be beneficial for structural alterations in patients with RA (Arthritis Rheum, 2006, 54: 1410-1414).